App-Quantinova.ai

PREDICTIVE MODEL FOR VEIN THROMBOEMBOLIC EVENTS DEVELOPMENT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

Mirjana Mitrovic - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Fibrinogen (IV)

PRIMARY ARTERIAL HYPERTENSION IN MYELOPROLIFERATIVE NEOPLASMS: A SYSTEMATIC REVIEW

Mihnea-Alexandru Gaman - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

N/A

INCREASED PREVALENCE OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH CONGENITAL DYSERYTHROPOIETIC ANEMIA TYPE I

Mahdi Asleh - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Venous thrombosis

N/A

FXI LEVELS AS INDEPENDENT RISK FACTOR FOR THROMBOSIS/OBSTETRIC EVENTS IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES

Mar�a Eugenia De La Morena-Barrio - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

N/A

IMPACT OF ACETYLSALICYLIC ACID DOSAGE ON INCIDENCE OF THROMBOSIS AND MORTALITY IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS.

Alexander Wild - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Albyl-E

CLINICAL IMPACT OF NON-ADHERENCE TO HIT GUIDELINES: A DOUBLE HIT IN HIT

Abdulrahman Al Raizah - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

Heparin

COMPARISON OF IMPROVE, MODIFIED IMPROVE, IMPROVEDD AND PADUA RISK SCORES FOR VENOUS THROMBOEMBOLISM PREDICTION IN HOSPITALIZED COVID-19 PATIENTS

Marko Lucijanic - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

N/A

THROMBOMODULIN RESISTANCE: A NEW PROTHROMBOTIC PATHWAY IN COVID-19

Adrin Montao - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Thrombomodulin alfa

THROMBOTIC COMPLICATIONS IN MERS-COV COMPARED TO COVID-19

Abdulrahman Al Raizah - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Venous thrombosis

N/A

HIGHER ESTIMATED PLASMA VOLUME STATUS IS ASSOCIATED WITH INCREASED THROMBOTIC RISK AND IMPAIRED SURVIVAL IN PATIENTS WITH PRIMARY MYELOFIBROSIS

Marko Lucijanic - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

N/A

ACUTE PROMYELOCYTIC LEUKEMIA AND THROMBOSIS: HOW TO IDENTIFY THE HIGH-RISK PATIENTS?

Mariem `Ben Salah - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Tretinoin

ENDOVASCULAR TREATMENT FOR UPPER AND LOWER EXTREMITYDEEP VEIN THROMBOSIS, CASE REPORTS

Adrian Casamayor Garcia - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

N/A

THROMBOSIS RISK ASSESSMENT IN LYMPHOMA PATIENTS - PROSPECTIVE PILOT SUDY

Darko Antic - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

N/A

SCREENING FOR PORTAL HYPERTENSION IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

Marta Davidson - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

POST-HOSPITAL DISCHARGE EVALUATION OF COVID-19 SURVIVORS WHO SUFFERED ACUTE VENOUS THROMBOEMBOLISM (VTE) DURING HOSPITALIZATION: THE BERGAMO EXPERIENCE

Chiara Ambaglio - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Fibrinogen (IV)

ASSOCIATION BETWEEN FRAILTY AND CLINICAL OUTCOMES IN MYELOPROLIFERATIVE NEOPLAMS: A POPULATION-BASED STUDY FROM ONTARIO, CANADA

Aniket Bankar - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

N/A

THROMBOTIC EVENTS DURING REMISSION INDUCTION OF ACUTE MYELOID LEUKEMIA – FREQUENCY AND RELATED FACTORS

Wellington Silva - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

N/A

MTHFR C677T GENOTYPE IN CORRELATION WITH THROMBOSIS AND ASSOCIATION WITH FVIII COAGULANT ACTIVITY IN GREEK PAEDIATRIC POPULATION

Stefanos Saslis - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

FVIII

ARTERIAL THROMBOSIS AND ACUTE MYELOID LEUKEMIA – IS THERE A CONNECTION?

Nikola Pantic - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Venous thrombosis

Fibrinogen (IV)

HEPARIN BRIDGING THERAPY IS ASSOCIATED WITH DELAYED BLEEDING AFTER ENDOSCOPIC TREATMENT FOR COMMON BILE DUCT STONE IN PATIENTS TREATED WITH ORAL ANTITHROMBOTIC THERAPY

Kappei Hayashi - Digestive Disease Week (DDW) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Heparin

Filters

7277 Abstracts